Experts say it isn't viable for drug companies that spend millions developing a new antibiotic medicine then to be told by regulators to hold it in reserve for the next emergency.
Then the volunteers will be given an antibiotic to essentially wipe out the population of M. smithii and the same parameters will be measured again, to see if eliminating the microbes will help change the patient's weight profile and alter their trajectory toward diabetes.